1. Home
  2. OTLY vs ACRS Comparison

OTLY vs ACRS Comparison

Compare OTLY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

SELL

Current Price

$7.28

Market Cap

454.4M

ML Signal

SELL

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

SELL

Current Price

$3.39

Market Cap

529.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OTLY
ACRS
Founded
1994
2012
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.4M
529.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
OTLY
ACRS
Price
$7.28
$3.39
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
★ $14.50
$10.27
AVG Volume (30 Days)
159.4K
★ 2.7M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.01
EPS
★ N/A
N/A
Revenue
N/A
★ $1,683,000.00
Revenue This Year
$11.81
N/A
Revenue Next Year
$6.35
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.07
$2.34
52 Week High
$16.20
$6.60

Technical Indicators

Market Signals
Indicator
OTLY
ACRS
Relative Strength Index (RSI) 28.11 36.10
Support Level N/A $3.24
Resistance Level $10.53 $3.44
Average True Range (ATR) 0.45 0.28
MACD -0.04 0.00
Stochastic Oscillator 11.19 4.02

Price Performance

Historical Comparison
OTLY
ACRS

About OTLY Oatly Group AB

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: